Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study.

MLA

Boudin, Laurys, et al. “Prognostic Impact of Hormone Receptor- and HER2-Defined Subtypes in Inflammatory Breast Cancer Treated with High-Dose Chemotherapy: A Retrospective Study.” Journal of Cancer, vol. 7, no. 14, Oct. 2016, pp. 2077–84. EBSCOhost, https://doi.org/10.7150/jca.15797.

APA

Boudin, L., Gonçalves, A., Sfumato, P., Sabatier, R., Bertucci, F., Tarpin, C., Provansal, M., Houvenaeghel, G., Lambaudie, E., Tallet, A., Resbeut, M., Charafe-Jauffret, E., Calmels, B., Lemarie, C., Boher, J.-M., Extra, J.-M., Viens, P., & Chabannon, C. (2016). Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. Journal of Cancer, 7(14), 2077–2084. https://doi.org/10.7150/jca.15797

Chicago

Boudin, Laurys, Anthony Gonçalves, Patrick Sfumato, Renaud Sabatier, François Bertucci, Carole Tarpin, Magali Provansal, et al. 2016. “Prognostic Impact of Hormone Receptor- and HER2-Defined Subtypes in Inflammatory Breast Cancer Treated with High-Dose Chemotherapy: A Retrospective Study.” Journal of Cancer 7 (14): 2077–84. doi:10.7150/jca.15797.